Literature DB >> 12888903

Two ways to induce innate immune responses in human PBMCs: paracrine stimulation of IFN-alpha responses by viral protein or dsRNA.

Philippe Fournier1, Jinyang Zeng, Volker Schirrmacher.   

Abstract

In order to study mechanisms of induction of IFN-alpha by Newcastle disease virus (NDV), we used two replicon systems which are based respectively on DNA and RNA of the Semliki forest virus (SFV) and transfected these into baby hamster kidney cells (BHK) which do not produce interferon-alpha. Co-incubation of BHK cells which were transfected with the two vector systems, with human PBMCs, showed that production of IFN-alpha takes place by two different ways. When using the DNA-based SFV vector, only transfectants expressing cell surface HN molecules of NDV (and not the mock-transfected cells) elicited such a response via interaction of these HN molecules with viral receptors on PBMCs. In contrast, BHK cells transfected with RNA which had been in vitro transcribed from the RNA-based SFV vector without foreign gene as insert (mock-transfected) elicited a comparable IFN-alpha response. Transfer by transfection of poly(I:C), an analogue of double stranded RNA (dsRNA), into the BHK cells induced also by itself the production of IFN-alpha. Therefore induction of "danger signals" (as double-strand RNA replicative intermediates) might be responsible for this discrepancy observed in IFN-alpha induction in PBMCs between the two studied SFV vector systems based on transfection of DNA and on RNA. These observations highlight two ways of IFN-alpha induction which additively may explain the high interferonogenic capacity of NDV as virus: i) via cell-surface expressed HN after transfection of the DNA-based SFV replicon and ii) via transfection of self-amplifying RNA.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12888903

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  11 in total

1.  Genetically engineered oncolytic Newcastle disease virus effectively induces sustained remission of malignant pleural mesothelioma.

Authors:  Gerd R Silberhumer; Peter Brader; Joyce Wong; Inna S Serganova; Mithat Gönen; Segundo Jaime Gonzalez; Ronald Blasberg; Dmitriy Zamarin; Yuman Fong
Journal:  Mol Cancer Ther       Date:  2010-09-21       Impact factor: 6.261

2.  Infection of Aedes albopictus Mosquito C6/36 Cells with the wMelpop Strain of Wolbachia Modulates Dengue Virus-Induced Host Cellular Transcripts and Induces Critical Sequence Alterations in the Dengue Viral Genome.

Authors:  Tadahisa Teramoto; Xin Huang; Peter A Armbruster; Radhakrishnan Padmanabhan
Journal:  J Virol       Date:  2019-07-17       Impact factor: 5.103

3.  Antitumor and immunostimulatory activities of a genotype V recombinant attenuated veterinary Newcastle disease virus vaccine.

Authors:  Oscar Antonio Ortega-Rivera; J Luis Quintanar; Susana Del Toro-Arreola; Ángel G Alpuche-Solis; Mayra J Esparza-Araiza; Eva Salinas
Journal:  Oncol Lett       Date:  2017-11-09       Impact factor: 2.967

Review 4.  Oncolytic virus therapy for cancer.

Authors:  Joe Goldufsky; Shanthi Sivendran; Sara Harcharik; Michael Pan; Sebastian Bernardo; Richard H Stern; Philip Friedlander; Carl E Ruby; Yvonne Saenger; Howard L Kaufman
Journal:  Oncolytic Virother       Date:  2013-09-23

Review 5.  Tumor antigen-dependent and tumor antigen-independent activation of antitumor activity in T cells by a bispecific antibody-modified tumor vaccine.

Authors:  Philippe Fournier; Volker Schirrmacher
Journal:  Clin Dev Immunol       Date:  2011-03-01

Review 6.  Safety and clinical usage of newcastle disease virus in cancer therapy.

Authors:  Han Yuen Lam; Swee Keong Yeap; Mehdi R Pirozyan; Abdul Rahman Omar; Khatijah Yusoff; Abd Aziz Suraini; Noorjahan Banu Alitheen
Journal:  J Biomed Biotechnol       Date:  2011-10-26

7.  Induction of apoptosis in MCF-7 cells by the hemagglutinin-neuraminidase glycoprotein of Newcastle disease virus Malaysian strain AF2240.

Authors:  Mohamed Ghrici; Mohamed El Zowalaty; Abdul Rahman Omar; Aini Ideris
Journal:  Oncol Rep       Date:  2013-06-27       Impact factor: 3.906

Review 8.  Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy.

Authors:  Volker Schirrmacher; Stefaan van Gool; Wilfried Stuecker
Journal:  Biomedicines       Date:  2019-08-30

Review 9.  Newcastle disease virus: a promising vector for viral therapy, immune therapy, and gene therapy of cancer.

Authors:  Volker Schirrmacher; Philippe Fournier
Journal:  Methods Mol Biol       Date:  2009

10.  Oncolysis by paramyxoviruses: multiple mechanisms contribute to therapeutic efficiency.

Authors:  Olga V Matveeva; Zong S Guo; Svetlana A Shabalina; Peter M Chumakov
Journal:  Mol Ther Oncolytics       Date:  2015-07-22       Impact factor: 7.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.